HR-dodatni rak piersi: badanie fazy III leku capecitabine i dexamethasone acetate
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2-…